Effectiveness of Highly Purified Cannabidiol in Refractory and Super-Refractory Status Epilepticus: A Case Series

被引:0
|
作者
Di Mauro, Giovanni [1 ,2 ]
Vietri, Giovanni [2 ]
Quaranta, Loreta [3 ,4 ]
Placidi, Fabio [1 ,2 ]
Izzi, Francesca [1 ,2 ]
Castelli, Alessandro [1 ,2 ]
Pagano, Andrea [1 ,2 ]
Leonardis, Francesca [5 ]
De Angelis, Viviana [5 ]
Bianco, Ciro [6 ]
Celeste, Maria Grazia [6 ]
Mercuri, Nicola Biagio [2 ]
Liguori, Claudio [1 ,2 ]
机构
[1] Univ Roma Tor Vergata, Dept Syst Med, Neurol Unit, Epilepsy Ctr, Viale Oxford 81, I-00133 Rome, Italy
[2] Univ Roma Tor Vergata, Dept Syst Med, Viale Oxford 82, I-00133 Rome, Italy
[3] S Eugenio Hosp, Epilepsy Ctr, Div Neurol, Piazzale Umanesimo 10, I-00144 Rome, Italy
[4] S Eugenio Hosp, Epilepsy Ctr, Stroke Unit, Piazzale Umanesimo 10, I-00144 Rome, Italy
[5] Univ Roma Tor Vergata, Dept Clin Sci & Translat Med, Intens Care Unit, Rome, Italy
[6] Univ Hosp Rome Tor Vergata, Clin Pharm, Rome, Italy
关键词
Status epilepticus; emergency; anti-seizure medication; epilepsy; seizure; lennox-gastaut syndrome; MANAGEMENT; SEIZURES; CB1;
D O I
10.2174/0118715273304077240603115521
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Introduction Refractory and super-refractory status epilepticus are medical emergencies that must be promptly treated in consideration of their high mortality and morbidity rate. Nevertheless, the available evidence of effective treatment of these conditions is scarce. Among novel antiseizure medications (ASMs), highly purified cannabidiol (hpCBD) has shown noteworthy efficacy in reducing seizures in Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), and Tuberous Sclerosis Complex (TSC).Case Presentation Here, we present two cases of effective use of hpCBD in both refractory and super-refractory status epilepticus. The administration of the nasogastric tube permitted the resolution of status epilepticus without adverse events. At 6-month follow-up, both patients were on hpCBD treatment, which continued to be efficacious for treating seizures.Conclusion According to our experience, hpCBD should be taken into consideration as an add-on therapy of RSE and SRSE while also considering the possibility of maintaining this treatment during the follow-up of patients. However, more studies and real-world experiences are needed to better understand its effectiveness in this setting and the interaction with other ASMs.
引用
收藏
页码:158 / 163
页数:6
相关论文
共 50 条
  • [31] Super-refractory status epilepticus: treatment with ketogenic diet in pediatrics
    Vaccarezza, Maria
    Silva, Walter
    Maxit, Clarisa
    Agosta, Guillermo
    REVISTA DE NEUROLOGIA, 2012, 55 (01) : 20 - 25
  • [32] Neuromodulation Techniques in Children with Super-Refractory Status Epilepticus
    Stavropoulos, Ioannis
    Pak, Ho Lim
    Alarcon, Gonzalo
    Valentin, Antonio
    BRAIN SCIENCES, 2023, 13 (11)
  • [33] Ketamine to treat super-refractory status epilepticus
    Alkhachroum, Ayham
    Der-Nigoghossian, Caroline A.
    Mathews, Elizabeth
    Massad, Nina
    Letchinger, Riva
    Doyle, Kevin
    Chiu, Wei-Ting
    Kromm, Julie
    Rubinos, Clio
    Velazquez, Angela
    Roh, David
    Agarwal, Sachin
    Park, Soojin
    Connolly, E. Sander
    Claassen, Jan
    NEUROLOGY, 2020, 95 (16) : E2286 - E2294
  • [34] Electroconvulsive Therapy in Refractory and Super-Refractory Status Epilepticus in Adults: A Scoping Review
    Ong, Marjorie Jia Yi
    Lee, Vanessa Lin Lin
    Teo, Sze Lynn
    Tan, Hui Jan
    Trinka, Eugen
    Khoo, Ching Soong
    NEUROCRITICAL CARE, 2024, : 681 - 690
  • [35] Lidocaine as a potential therapeutic option for super-refractory status epilepticus: A case report
    Sugata, Mayu
    Kataoka, Hiroshi
    Uchihara, Yuto
    Shimada, Daisuke
    Atagi, Kazuaki
    Nakamura, Michitaka
    Hara, Makoto
    Kawahara, Makoto
    Sugie, Kazuma
    JOURNAL OF CENTRAL NERVOUS SYSTEM DISEASE, 2023, 15
  • [37] (S)-Ketamine in Refractory and Super-Refractory Status Epilepticus: A Retrospective Study
    Julia Höfler
    Alexandra Rohracher
    Gudrun Kalss
    Georg Zimmermann
    Judith Dobesberger
    Georg Pilz
    Markus Leitinger
    Giorgi Kuchukhidze
    Kevin Butz
    Alexandra Taylor
    Helmut Novak
    Eugen Trinka
    CNS Drugs, 2016, 30 : 869 - 876
  • [38] Burden of illness for super-refractory status epilepticus patients
    Beg, Jamil M.
    Anderson, Thomas D.
    Francis, Kevin
    Meckley, Lisa M.
    Fitzhenry, David
    Foster, Todd
    Sukhtankar, Susheel
    Kanes, Stephen J.
    Moura, Lidia M. V. R.
    JOURNAL OF MEDICAL ECONOMICS, 2017, 20 (01) : 45 - 53
  • [39] Perampanel in patients with refractory and super-refractory status epilepticus in a neurological intensive care unit
    Rohracher, A.
    Hoefler, J.
    Kalss, G.
    Leitinger, M.
    Kuchukhidze, G.
    Deak, I.
    Dobesberger, J.
    Novak, H.
    Pilz, G.
    Zerbs, A.
    Trinka, E.
    EPILEPSY & BEHAVIOR, 2015, 49 : 354 - 358
  • [40] Responsive neurostimulation as a treatment for super-refractory focal status epilepticus: a systematic review and case series
    Ernst, Lia D.
    Raslan, Ahmed M.
    Wabulya, Angela
    Shin, Hae Won
    Cash, Sydney S.
    Yang, Jimmy C.
    Sagi, Vishwanath
    King-Stephens, David
    Damisah, Eyiyemisi C.
    Ramos, Alexander
    Hussain, Batool
    Toprani, Sheela
    Brandman, David M.
    Shahlaie, Kiarash
    Kanth, Kiran
    Arain, Amir
    Peters, Angela
    Rolston, John D.
    Berns, Meaghan
    Patel, Sima I.
    Uysal, Utku
    JOURNAL OF NEUROSURGERY, 2024, 140 (01) : 201 - 209